Hydroxychloroquine and Cardiovascular Events in Patients with Rheumatoid Arthritis

ABSTRACT:

Introduction

Cardiovascular disease (CVD) is the leading cause of mortality in patients with rheumatoid arthritis (RA). Some studies have reported a decrease in CVD in patients with RA using hydroxychloroquine (HCQ). Most of these have had fewer participants and have analyzed only composite outcomes. We aimed to identify the association between the use of HCQ in patients with RA and the incidence of major adverse cardiac events (MACEs), cerebral infarction, and AMI.

Methods

This was a retrospective observational study using the TriNetX Diamond Network. Propensity score matching (PSM) was used to equilibrate the cohorts. The dependent variables in our study were MACE, cerebral infarction, and AMI.

Results

A total of 2,261,643 patients with RA were identified. Appr

SUBMITTER: Cordova Sanchez A 

PROVIDER: S-EPMC9532807 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature